To eliminate Tuberculosis (TB), we need shorter and effective treatment regimens.
The World Health Organization (WHO) defines ‘cured TB’ as: “A pulmonary TB patient with bacteriologically confirmed TB at the beginning of treatment
who was smear- or culture-negative in the last month of treatment and on at least
one previous occasion”. At present, for drug susceptible TB, culture conversion at two months of treatment
is used as a primary surrogate endpoint for treatment response
1
, which is often debated because of weak correlation with treatment outcomes. Valid
early surrogate markers could help in predicting long-term treatment outcomes, reduce
costs and time, and revolutionize TB treatment.
2
,
3
Exhaled breath, composed of volatile organic compounds (VOCs), might have potential
to reflect disease activity. These ‘smell prints’, picked up by an electronic nose
(eNose) device, are either VOCs from the host, the pathogen or their interplay.
- Nahid P.
- Dorman S.E.
- Alipanah N.
- Barry P.M.
- Brozek J.L.
- Cattamanchi A.
- et al.
Official American thoracic society/centers for disease control and prevention/infectious
diseases society of America clinical practice guidelines: treatment of drug-susceptible
tuberculosis.
Clin Infect Diseas Official Publ Inf Diseases Soc Am. 2016; 63: e147-ee95
4
,
5
In an earlier study, the Aeonose™ showed excellent performance in differentiating
healthy persons from TB patients, with a sensitivity and specificity of 91% and 93%,
respectively.
6
This study investigated if smell print samples in TB patients have potential in predicting
treatment response and its possible confounders, aiming to explore the utility of
VOCs as an early biomarker in TB treatment.To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of InfectionAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- [Short term chemotherapy of tuberculosis. Factors affecting relapse following short term chemotherapy].Bull Int Union Tuberc. 1978; 53: 276-280
- CDC/NIH Workshop. Tuberculosis biomarker and surrogate endpoint research roadmap.Am J Respir Crit Care Med. 2011; 184: 972-979
- Official American thoracic society/centers for disease control and prevention/infectious diseases society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis.Clin Infect Diseas Official Publ Inf Diseases Soc Am. 2016; 63: e147-ee95
- Point-of-care breath test for biomarkers of active pulmonary tuberculosis.Tuberculosis. 2012; 92: 314-320
- Diagnosis of pulmonary tuberculosis and assessment of treatment response through analyses of volatile compound patterns in exhaled breath samples.J Infect. 2017; 74: 367-376
- The potential of a portable, point-of-care electronic nose to diagnose tuberculosis.J Infect. 2017;
- Sputum monitoring during tuberculosis treatment for predicting outcome: systematic review and meta-analysis.Lancet Infect Diseas. 2010; 10: 387-394
- Paradoxical reactions and immune reconstitution inflammatory syndrome in tuberculosis.Int J Infect Diseas IJID Offic Publ Int Soc Infect Diseas. 2015; 32: 39-45
- The within-host population dynamics of Mycobacterium tuberculosis vary with treatment efficacy.Genome Biol. 2017; 18: 71
- An evaluation of culture results during treatment for tuberculosis as surrogate endpoints for treatment failure and relapse.PLoS ONE. 2013; 8: e63840
Article info
Publication history
Published online: June 28, 2020
Accepted:
June 26,
2020
Identification
Copyright
© 2020 The British Infection Association. Published by Elsevier Ltd. All rights reserved.
